MarginsXMarginsX
Home › Markets › Health Care › CNSP

CNS Pharmaceuticals Inc. (CNSP)

CNSP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.48
+20.42% on the day
Market cap
$5.1M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerCNSP on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2019
SEC CIK0001729427
SEC industry codePharmaceutical Preparations
Incorporated inNV

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
17.9 months
$20.0M cash at June 30, 2026
Share count, 1 year
+154.4%
2025-08-14 to 2026-08-11 · +1043312.7% over 3 years
Going-concern doubt
No
10-Q filed August 12, 2026
Insider net buying, 12 months
$44K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-08-12
Cash and burn$20.0M cash; operating cash flow -$3.4M a quarter.Report 2026-06-30
Shares outstanding1,461,449 (2026-08-11); 574,580 a year earlier; 4,201,930 three years earlier. 3y figure adjusted for splits (1-for-30000 overall).Cover page 2026-08-11
Reverse splits, 3 years3; latest 1-for-12 on 2025-07-22Source 2025-07-22
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-05-19
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorMaloneBailey, LLP, Houston, Texas, United StatesPCAOB Form AP 2026-04-07
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $44K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$2.6M-$3.5M$20.0M$300KNeeds four quarters10-Q 2026-08-12
Q1 2026
2026-03-31
Not filed-$4.9M-$4.6M$3.0M$232KNeeds four quarters10-Q 2026-08-12
Q4 2025
2025-12-31
Not filed-$6.0M-$3.1M$7.2M$628KNeeds four quarters10-K 2026-03-31
Q3 2025
2025-09-30
Not filed-$3.2M-$2.2M$9.9M$31KNeeds four quarters10-Q 2025-11-14
Q2 2025
2025-06-30
Not filed-$2.4M-$5.3M$12.1M$122KNeeds four quarters10-Q 2026-08-12
Q1 2025
2025-03-31
Not filed-$4.3M-$3.2M$13.0M$211KNeeds four quarters10-Q 2026-08-12
Q4 2024
2024-12-31
Not filed-$3.2M-$5.5M$6.5M$326KNeeds four quarters10-K 2026-03-31
Q3 2024
2024-09-30
Not filed-$5.6M-$6.8M$7.0M$31KNeeds four quarters10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
424B3 PROSPECTUS
424B32026-05-26
Latest annual report
AMENDMENT #1 TO FORM 10-K
10-K/A2026-04-30
Latest quarterly / interim
FORM 10-Q FOR SEP 2026
10-Q2026-11-16
Latest current report
FORM 8-K
8-K2026-10-02
Latest proxyDEFA14A2026-08-25

Source: SEC EDGAR submissions feed, 391 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-26.3%
1 month-46.0%
3 months-43.9%
Year to date-45.0%
1 year-55.2%
From 52-week high-63.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
JAGXJaguar Health Inc.$0.3864-7.74%$5.2M
CVKDCadrenal Therapeutics Inc.$1.40-7.28%$5.0M
SCNXScienture Holdings Inc.$2.99+3.10%$4.9M
PULMPulmatrix Inc.$1.33+2.31%$4.9M
PCSAProcessa Pharmaceuticals Inc.$1.72-7.53%$4.8M
CANFCan-Fite Biopharma Ltd$1.56+9.86%$4.7M
SKYESkye Bioscience Inc.$1.06-2.29%$4.7M
ACXPAcurx Pharmaceuticals Inc.$0.9350-2.60%$5.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier